共 46 条
[1]
Hesketh PJ(2016)Antiemetics: American Society of Clinical Oncology focused guideline update J Clin Oncol 34 381-386
[2]
Bohlke K(2015)Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan Int J Clin Oncol 20 855-865
[3]
Lyman GH(2015)Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin Support Care Cancer 23 3317-3322
[4]
Tamura K(2011)Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy Support Care Cancer 19 807-813
[5]
Aiba K(2016)Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis Cancer Sci 104 711-717
[6]
Saeki T(2015)Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with palonosetron Cancer Sci 106 891-895
[7]
Furukawa N(2015)Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial Eur J Cancer 51 1274-1282
[8]
Kanayama S(2016)Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin Int J Clin Oncol 21 491-497
[9]
Tanase Y(2013)A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy Br J Cancer 109 859-865
[10]
Ito F(2016)Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing after highly emetogenic chemotherapy: TRIPLE study Ann Oncol 27 1601-1606